广州慧谷新材料科技股份有限公司 股票简称：慧谷新材 股票代码：301683 （广州经济技术开发区新业路 62 号） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 二〇二六年三月 广州慧谷新材料科技股份有限公司 上市公告书 第一节 重要声明与提示 特别提示 广州慧谷新材料科技股份有限公司（以下简称"慧谷新材""本公司""公司"或 "发行人"）股票将于 2026 年 4 月 1 日在深圳证券交易所上市。 创业板公司具有业绩不稳定、经营风险高、退市风险高等特点，投资者面临较大的 市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因素，审慎 作出投资决定。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词释义与《广州慧谷新材料科技股份有 限公司首次公开发行股票并在创业板上市招股说明书》（以下简称"招股说明书"）中 的相同。如本上市公告书中合计数与各加数直接相加之和在尾数上存在差异，系由于四 舍五入所致 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has received a report from CITIC Securities regarding the initial public offering (IPO) and listing guidance for Bailin Pharmaceutical Technology (Shanghai) Co., Ltd. [1][11] - Bailin Pharmaceutical is a high-tech enterprise located in Shanghai, focusing on providing process solutions for the life sciences sector, including the development and manufacturing of key process equipment and consumables for recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biological products [1][11] - The company was established on September 10, 2021, with a registered capital of 360 million yuan [4][14] Group 2 - The controlling shareholder of Bailin Pharmaceutical is Hainan Bailin Technology Investment Center (Limited Partnership), which holds 100,068,120 shares, accounting for 27.7967% of the company [5][12] - Bailin Pharmaceutical has received investments from various institutions, including Shenzhen Capital Group, K2VC, Qingsong Capital, and Sherpa Capital [2][12] Group 3 - The guidance agreement for the IPO was signed on February 24, 2026, with CITIC Securities as the guiding institution, Beijing Jingtian & Gongcheng Law Firm as the legal advisor, and Rongcheng Certified Public Accountants as the accounting firm [6][15][16] - The guidance work includes comprehensive due diligence on the company's historical development, training on relevant laws and regulations, and preparation for compliance with listing requirements [7][16]

Company Overview - Chengdu Hehong Technology Co., Ltd. is primarily engaged in the production and manufacturing of aviation civil engine components and aircraft structural components [1][4] - The company was established on September 28, 2003, with a registered capital of 211.811071 million yuan [4] - The legal representative is Zhou Leli, and the company is located in the Chengdu Economic and Technological Development Zone [4] Shareholding Structure - The controlling shareholder is Shanghai Yinghe Asset Management Co., Ltd., holding 60.429834 million shares, which accounts for 28.53% of the total share capital [1][4] Financing History - Hehong Technology has received investments from various institutions, including Aviation Development Fund, Sichuan Development, Shanghai Kechuang, Zhangjiang Torch Venture Capital, Huacang Capital, and Haiwang Capital [2] - The company has undergone multiple financing rounds, including a C+ round in September 2022, a C$2 round in July 2021, and a B$8 round in July 2019, with undisclosed amounts [3] IPO Guidance Information - The company has submitted a report for the guidance of its initial public offering (IPO) to the China Securities Regulatory Commission, with Jiangsu Securities as the guiding institution [1][5] - The guidance agreement was signed on February 12, 2026, and the legal and accounting firms involved are Shanghai Jintiancheng Law Firm and Xinyong Zhonghe Accounting Firm [5] Guidance Work Arrangement - The guidance work includes training on securities knowledge, market overview, and relevant laws, scheduled from February to May 2026 [6][7][8] - Various methods such as lectures, consultations, and meetings will be employed to ensure comprehensive understanding and compliance with IPO requirements [6][7][8]

股票简称：世盟股份 股票代码：001220 世盟供应链管理股份有限公司 Shimeng Supply Chain Management Co., Ltd. （北京市北京经济技术开发区西环南路 36 号院 8 号楼） 首次公开发行股票并在主板上市 之 上市公告书 保荐人（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二六年二月 世盟供应链管理股份有限公司 上市公告书 特别提示 世盟供应链管理股份有限公司（以下简称"世盟股份"、"本公司"、"公 司"或"发行人"）股票将于 2026 年 2 月 3 日在深圳证券交易所（以下简称"深 交所"）主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 除非文中另有所指，本上市公告书中所使用的简称或词语含义与《世盟供应 链管理股份有限公司首次公开发行股票并在主板上市招股说明书》（以下简称"招 股说明书"）一致。 本上市公告书中若出现总计数与各分项数值之和尾数不符的情形，均为四舍 五入所致。 1 世盟供应链管理股份有限公司 上市公告书 第一节 重要 ...

Company Overview - Shenzhen Huake Precision Industry Co., Ltd. was established in 2004 and focuses on the research, production of precision metal and plastic components, connectors, and precision stamping and injection molds, with applications in communication, automotive, medical, industrial control, and consumer electronics sectors [1][2]. - The legal representative of the company is Du Liuxue [1]. Shareholding Structure - As of the report date, Shenzhen Huake Precision Holdings Co., Ltd. directly holds 28.5 million shares, representing a 41.56% stake, making it the controlling shareholder of the company [1][2]. IPO Guidance Status - On January 29, 2026, the China Securities Regulatory Commission disclosed that Guotai Junan Securities has submitted the "Guidance Filing Report for the Initial Public Offering and Listing of Shenzhen Huake Precision Industry Co., Ltd." The current guidance status is "Guidance Filing" [1]. - The guidance agreement was signed on January 19, 2026, with Guotai Junan Securities as the guiding institution, Guangdong Huashang Law Firm as the legal advisor, and Zhongshen Zhonghuan Accounting Firm (Special General Partnership) as the accounting firm [3][4]. Guidance Process - The guidance process includes several stages: - Preliminary stage involves due diligence and developing a specific guidance plan based on the company's situation, with regular coordination meetings among intermediary institutions [4]. - During the guidance phase, training sessions will be conducted for the personnel of the company, covering capital market fundamentals, legal regulations, and internal control systems [6]. - The post-guidance phase focuses on preparing the application documents for the initial public offering and ensuring compliance with regulatory requirements [6].

Core Viewpoint - Rongke Technology (300290) clarified on its interactive platform that it distinguishes between "counseling filing" and "submission of application materials" in accordance with the China Securities Regulatory Commission's regulations for companies applying for initial public offerings [1] Group 1 - The company responded to investor inquiries regarding its IPO process [1] - The clarification emphasizes that the company is not confusing the terms related to the IPO application process [1]

股票简称：至信股份 股票代码：603352 重庆至信实业股份有限公司 Chongqing Zhixin Industrial Co., Ltd （重庆市江北区鱼嘴镇长惠路 29 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） （新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室） 联席主承销商 重庆至信实业股份有限公司 上市公告书 特别提示 重庆至信实业股份有限公司（以下简称"至信股份""发行人""本公司" 或"公司"）股票将于 2026 年 1 月 15 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词释义与本公司首次公开发行股 票并在主板上市招股说明书中的相同。如本上市公告书中合计数与各加数直接相 加之和在尾数上存在差异，系由于四舍五入所致。 2 （重庆市江北区金沙门路 32 号） 重庆至信实业股份有限公司 上市公告书 公告日期：二〇二六年一月一十四日 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事 ...

首次公开发行股票并在主板上市 内蒙古双欣环保材料股份有限公司 （鄂托克旗蒙西高新技术工业园） 股票简称：双欣环保 股票代码：001369 之 上市公告书 保荐人（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年十二月 内蒙古双欣环保材料股份有限公司 上市公告书 特别提示 内蒙古双欣环保材料股份有限公司（以下简称"双欣环保""本公司""公 司"或"发行人"）股票将于 2025 年 12 月 30 日在深圳证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与《内蒙古双欣环保材 料股份有限公司首次公开发行股票并在主板上市招股说明书》（以下简称"招股 说明书"）中的相同。 本上市公告书中若出现总计数与各分项数值之和尾数不符的情形，均为四舍 五入所致。 1 内蒙古双欣环保材料股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、高级管理人员保证上市公告书的真实性、准确性、完整 性，承诺上市公告书 ...

股票简称：元创股份 股票代码：001325 元创科技股份有限公司 YACHOO TECHNOLOGY CO., LTD. （浙江省台州市三门县海润街道旗海路 55 号） 首次公开发行股票并在主板上市之 上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年十二月 特别提示 元创科技股份有限公司（以下简称"元创股份"、"发行人"、"公司"、"本公 司"）股票将于 2025 年 12 月 18 日在深圳证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在主板上市招股说明书中的相同。如本上市公告书中合计数与各加数直接 相加之和在尾数上存在差异，系四舍五入所致。 本上市公告书"报告期"指：2022 年度、2023 年度、2024 年度、2025 年 1-6 月。 1 | 目录 | | --- | | 目录 2 | | --- | | 第一节 重要声明与提示 4 | | 一、重要声明 4 | | 二、主板新股上市 ...

Core Points - The China Securities Regulatory Commission (CSRC) announced that CITIC Securities has submitted the completion report for the initial public offering (IPO) and listing guidance of Shenzhen Hanno Medical Technology Co., Ltd. The current status of Hanno Medical is "guidance acceptance" [1][25] - Hanno Medical, established in 2018 and located in Shenzhen, Guangdong Province, primarily engages in wholesale activities. The legal representative is Li Mingtang [1][25] - The controlling shareholder of Hanno Medical is Beijing Hanno Medical Technology Co., Ltd., which holds a 24.85% stake in the company [26] Financing History - Hanno Medical has undergone several financing rounds, including: - E+ round on June 21, 2024, raising nearly 100 million RMB [27] - E round on January 5, 2024, raising over 100 million RMB [28] - D round on February 23, 2023, with undisclosed financing [28] - C round on July 29, 2022, raising over 100 million RMB [28] - B round on February 15, 2022, with undisclosed financing [28] - A round on November 16, 2021, with undisclosed financing [28] - Angel round on October 27, 2020, with undisclosed financing [28] Company Governance Issues - During the reporting period, Hanno Medical established an internal governance structure and management system. However, with rapid business growth, there are areas for improvement in organizational management, operational capabilities, and risk control systems [3][39] - The intermediary institutions have assisted in enhancing governance by investigating and improving internal control systems and reviewing governance documents [4][30] Fundraising Project Issues - The guidance institution has worked with Hanno Medical to refine its fundraising project planning and ensure the smooth progress of fundraising projects, including feasibility report assessments [5][31] - Hanno Medical has cooperated with the guidance institution to conduct thorough research and discussions on the fundraising investment plan, confirming the specific uses and investment scale of the funds raised [6][32] Social Insurance and Housing Fund Issues - The guidance institution identified that Hanno Medical had not timely paid social insurance and housing funds for some employees during the reporting period [7][33] - Hanno Medical has taken steps to address these issues, including obtaining proof from administrative authorities that no penalties were imposed for these lapses [8][34]